Ag85A, As an S2 Vaccine Carrier, Reduces the Toxicity of the S2 Vaccine and Enhances the Protective Ability of Mice against Brucella

Figure 5

Enhancement of the cytokines stimulation by S2-Ag85A oral vaccine in mice. (a) The significantly elevated level of SIgA secreted by S2-Ag85A in the intestinal tract of mice than that in the S2 group ( value < 0.05). (b) The secretion of SIgA is augmented in peripheral serum and spleen tissue of mice after the application of S2-Ag85A vaccine. (c) The level of IL-1β is inhibited in peripheral serum and spleen tissue of mice after the application of S2-Ag85A vaccine ( value < 0.05). (d) The level of TNF-α is inhibited in the mouse spleen tissue after the application of S2-Ag85A vaccine (). (e) The level of IL-6 is inhibited in the mouse spleen tissue after the application of S2-Ag85A vaccine (). value < 0.05 compared with the S2 group.

(a)

(b)

(c)

(d)

(e)